Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy.

about

The effect and safety of anacetrapib in the treatment of dyslipidemia: a systematic review and meta-analysis.Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?

P2860

Q47405486-2C3BBFA9-1B9C-43D8-BD72-BE911B82F7B6 Q47726362-F89331E6-C00A-4214-8ECA-5BF7296DF094

P2860

Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy.

Item

http://www.wikidata.org/entity/Q42357375

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy.

@en

Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy.

@nl

type

Item

label

Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy.

@en

Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy.

@nl

prefLabel

Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy.

@en

Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy.

@nl

P1476

Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy.

@en

P2093

Moses S Elisaf

http://www.w3.org/2001/XMLSchema#string

Theodosios D Filippatos

http://www.w3.org/2001/XMLSchema#string

P2860

High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target

Effects of torcetrapib in patients at high risk for coronary events

Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion

ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.

Loss-of-function mutations in APOC3 and risk of ischemic vascular disease.

Is raising HDL a futile strategy for atheroprotection?

Biological activities of HDL subpopulations and their relevance to cardiovascular disease.

Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients.

P304

2308-2310

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.21037/JTD.2017.07.75

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28932532

http://www.w3.org/2001/XMLSchema#string

P932

5594181

http://www.w3.org/2001/XMLSchema#string

Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy.

about

P2860

P2860

Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932